← Back to home

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)

Clinical trials for EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.

Never miss a new study

Get alerted when new EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC) trials appear

Sign up with your email to follow new studies for EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New targeted drug trial offers hope for Tough-to-Treat cancers

Disease control Recruiting now

This study is testing a new drug called Rina-S in people whose solid tumor cancers have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for people with several types of advanced cancer, including ovarian,…

Matched conditions: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)

Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control

Last updated Mar 12, 2026 13:51 UTC

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)

Get alerted when new EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC) trials appear

New targeted drug trial offers hope for Tough-to-Treat cancers